The federal government issued a notice of proposed rulemaking that would postpone its revisions to the Common Rule on the use of human subjects in clinical trials for another six months and opened up discussion on the permitting of three burden-reducing provisions in the 2018 requirements for regulated entities.
Source: Drug Industry Daily